natgillin/translations-raw huggingface dataset:
Det skal i denne forbindelse præciseres, at Kommissionen i beslutning 1999/509 ikke har fastsat en frist for gennemførelsen af de i beslutningen krævede foranstaltninger, og at der inden for rammerne af undtagelsesordningen for traktatbrudssøgsmål i henhold til artikel 88, stk. 2, andet afsnit, EF, ikke gælder en bestemt frist for gennemførelsen.
In addition, the Commission does not dispute that the creditors' meeting decided to put Indosa into liquidation.
Kommissionen fastsatte dog i artikel 3 i beslutning 1999/509 en frist på to måneder, der udløb den 29. december 1998, inden for hvilken de spanske myndigheder skulle underrette Kommissionen om de foranstaltninger, de havde truffet til gennemførelse af beslutningen.
In relation to that company, the Spanish authorities took the measures necessary to comply with Decision 1999/509.
Selv om den spanske regering har gjort gældende, at den kun har overtaget Gursas aktiver, er det ubestridt, at hverken TSS eller skatteministeriet har forsøgt at få Gursa og Migsa likvideret, hvorfor regeringen ikke kan godtgøre, at det var absolut umuligt, at der var andre aktiver, der kunne gøres udlæg i.
It is common ground that the Spanish Government did not inform the Commission before the expiry of the deadline of the measures which had already been taken and those which would be taken to recover the aid granted to Indosa, Cunosa, Migsa and Gursa and in particular, in the circumstances of this case, to recover Indosa's social security and fiscal debts.
Hvad angår Cunosa, var likvidationen allerede indledt, da Kommissionen vedtog beslutning 1999/509, men det fremgår ikke af sagens akter, om de spanske myndigheder under denne procedure har taget skridt til at tilbagesøge den ulovlige støtte i dette selskabs aktiver, selv om de efterfølgende har appelleret afgørelsen om at likvidere Cunosa, hvilket er sket for sent og uden tvivl ikke har ført til det ønskede resultat.
The Commission argues, nevertheless, that in any event, the measures adopted by the Kingdom of Spain were not taken within the period of two months from the notification of the Decisions 91/1 and 1999/509, so that the infringement of Article 3 of those decisions is established.
Det er imidlertid ubestridt, at den spanske regering ikke inden udløbet af fristen har underrettet Kommissionen om de foranstaltninger, der allerede var truffet, og de foranstaltninger, der ville blive truffet for at tilbagesøge den støtte, der var ydet til Indosa, Cunosa, Migsa og Gursa, og i denne sag navnlig for at inddrive Indosas skyldige sociale bidrag og skatter.
In that regard, it should be observed that the Commission did not set any deadline in Decision 1999/509 for the implementation of the measures required by that decision and there is no legal time-limit for implementation within the framework of the exceptional rules for bringing an action for failure to comply, based on the
Der skal derfor, for så vidt angår beslutning 1999/509, gives medhold i traktatbrudspåstanden i sin helhed, for så vidt det gøres gældende, at Kongeriget Spanien ikke har truffet de nødvendige foranstaltninger for at tilbagesøge den støtte, der er ydet Cunosa, Gursa og Migsa.
Consequently, in respect of Decision 1999/509, the action must be considered as entirely founded in so far as the Kingdom of Spain is accused of having failed to take the measures necessary to recover the aid granted to Gursa, Migsa and Cunosa.
Derimod skal der, for så vidt det gøres gældende, at Kongeriget Spanien ikke har truffet de nødvendige foranstaltninger for at tilbagesøge den støtte, der er ydet selskabet Indosa, kun gives medhold i traktatbrudspåstanden med hensyn til den manglende underretning af Kommissionen.
On the other hand, in so far as the Kingdom of Spain is accused of not having taken the measures necessary to recover the aid granted to Indosa, the infringement action is founded only in respect of the failure to inform the Commission.
Hvad derimod angår Indosa, som det fremgår ovenfor, har TSS og skatteministeriet på to forskellige måder godtgjort, at de har udvist passende omhu for at tilbagesøge såvel skyldige skatter som skyldige sociale bidrag. Kommissionen har i øvrigt ikke bestridt, at kreditorsamlingen besluttede at likvidere Indosa.
Declares that, first, by failing to adopt, within the prescribed period, the necessary measures to comply with Commission Decision 91/1/EEC of 20 December 1989 concerning aids in Spain which the central and several autonomous governments granted to Magefesa, producer of domestic articles of stainless steel and small electric appliances, in so far as it declared the aid granted to Industrias Domésticas SA (Indosa), Manufacturas Gur SA (Gursa), Manufacturas Inoxidables Gibraltar SA (Migsa) and Cubería del Norte SA (Cunosa) illegal and incompatible with the common market and with Commission Decision 1999/509/EC of 14 October 1998 concerning aid granted by Spain to companies in the Magefesa group and their successors, in so far as it declared the aid granted to Gursa, Migsa and Cunosa illegal and incompatible with the common market, and second, by failing to inform the Commission, within the prescribed period, of measures taken to implement Decision 1999/509 in so far as it declared aid granted to Indosa illegal and incompatible with the common market, the Kingdom of Spain has failed to fulfil its obligations under the fourth paragraph of Article 249 EC and Articles 2 and 3 of those decisions;
Det må derfor tiltrædes, at de spanske myndigheder, for så vidt angår dette selskab, har truffet de nødvendige foranstaltninger for at efterkomme beslutning 1999/509.
For the rest, dismisses the Commission's action;
Generaladvokat J. Mischo fremsatte forslag til afgørelse i retsmødet fSjette Afdeling') den 24. januar 2002.
Advocate General J. Mischo delivered his Opinion at the sitting of the Sixth Chamber on 24 January 2002.
Sag C-173/01 Kommissionen for De Europæiske Fællesskaber / Den Hellenske Republik Landbrug
Case C-173/01 Commission of the European Communities ν Hellenic Republic Agriculture
»Traktatbrud — direktiv 1999I20IEF — manglende gennemførelse inden for den fastsatte frist« (Fjerde Afdeling)
Republic had fulfilled its obligations in that regard, the Commission put the Greek Government on formal notice, by letter of 18 February 2000, to submit its observations on that point within two months.
Ved stævning indleveret til Domstolens Justitskontor den 20. april 2001 har Kommissionen for De Europæiske Fællesskaber i medfør af artikel 226 EF anlagt sag med påstand om, at det fastslås, at Den Hellenske Republik har tilsidesat sine forpligtelser i
By application lodged at the Court Registry on 20 April 2000, the Commission of the European Communities brought an action under Article 226 EC for a declaration that, by failing to adopt within the period prescribed the laws, regulations and administrative provisions necessary to comply with Council Directive 1999/20/EC of 22 March 1999 amending Directives 70/524/EEC concerning additives in feedingstuffs, 82/471/EEC concerning certain products used in animal nutrition, 95/53/EC fixing the principles governing the organisation of official inspections in the field of animal nutrition and 95/69/EC laying down the conditions and arrangements for approving and registering certain establishments and intermediaries operating in the animal feed sector, the Hellenic Republic has failed to fulfil its obligations under the EC Treaty and the Directive.
Da Kommissionen ikke modtog nogen oplysninger fra den græske regering, der kunne godtgøre, at de nødvendige love og administrative bestemmelser til gennemførelse af direktivet var blevet vedtaget, har den besluttet at anlægge denne sag.
department and that the draft presidential decree enacting them will, as soon as it is published, be forwarded to the Court and the Commission in its definitive version.
Generaladvokat A. Tizzano fremsatte forslag til afgørelse i retsmødet CFjerde Afdeling) den 2. maj 2002.
Advocate General A. Tizzano delivered his Opinion at the sitting of the Fourth Chamber on 2 May 2002.
»1) Den Hellenske Republik har tilsidesat sine forpligtelser i henhold til Rådets direktiv 1999/20/EF af 22. marts 1999 om ændring af direktiv 70/524/EØF om tilsætningsstoffer til foderstoffer, direktiv 82/471/EØF om visse produkter, der anvendes i foderstoffer, direktiv 95/53/EF om principperne for tilrettelæggelse af offentlig kontrol på foderstofområdet og direktiv 95/69/EF om betingelser og
declare that by not adopting the laws, regulations and administrative provisions necessary to comply with Council Directive 1999/20/EC amending Directives 70/524/EEC concerning additives in feedingstuffs, 82/471/EEC concerning certain products used in animal nutrition, 95/53/EC fixing the principles governing the organisation of official inspections in the field of animal nutrition and 95/69/EC laying down the conditions and arrangements for approving and registering certain establishments and intermediaries operating in the animal feed sector, the Hellenic Republic has failed to fulfil its obligations under that directive and under the EC Treaty;
Den Hellenske Republik betaler sagens omkostninger.«
2' — Absolute grounds for refusal — Article 7(1)(b) and (c) of Regulation (EC) No 40/94 - Equal treatment) (Second Chamber)
Sag T-323/00 SAT.l SatellitenFernsehen GmbH / Kontoret for Harmonisering i det Indre Marked (Varemærker og Design) (KHIM) Intellektuel ejendomsret
Case T-l79/00 A. Menarini - Industrie Farmaceutiche Riunite ν Commission of the European Communities Free movement of goods
»EF-varemærker — ordkombinationen SAT.2 — absolutte registreringshindringer stk 1, litra b) og c), i forordning (EF) nr. 40/94 — ligebehandling« (Anden Afdeling)
(Council Directive 92/27/EEC — Labelling of a medicinal product - Centralised procedure for the authorisation of medicinal products — Inclusion of the local representative's logo in the blue box on the outer packaging of a medicinal product) (Fourth Chamber)
Ved afgørelse af 9. april 1999 afslog undersøgeren delvist ansøgningen i henhold til artikel 38 i forordning nr. 40/94. Afgørelsens første og tredje afsnit har følgende ordlyd:
The applicant is a company incorporated under Italian law engaged in pharmaceutical research, medicinal product development and marketing.
Sagsøgeren indgav den 15. april 1997 i henhold til Rådets forordning (EF) nr. 40/94 af 20. december 1993 om EF-varemærker, med senere ændringer, en EF-varemærkeansøgning vedrørende et ordmærke til Kontoret for Harmonisering i det Indre Marked (Varemærker og Design) (herefter »Harmoniseringskontoret«).
for the medicinal product 'OPTRUMA', a proprietary medicinal product containing the pharmacologically active substance 'raloxifene', which is indicated for the treatment and prevention of osteoporosis in post-menopausal women.
Af de allerede angivne årsager afvises det at registrere tegnet som varemærke i henhold til artikel 7, stk. 1, litra b), i forordning nr. 40/94 for alle de af ansøgningen omfattede tjenesteydelser, i det omfang de henviser til satellitter eller satellit-tv i bredeste forstand.
On 5 August 1998, the Commission issued a marketing authorisation under the centralised procedure to Eli Lilly Nederland BV (hereinafter 'Eli Lilly'), a Dutch pharmaceutical company.
Ved skrivelse af 11. november 1998 meddelte undersøgeren sagsøgeren, at de absolutte registreringshindringer i artikel 7, stk. 1, litra b)
On 3 September 1999, Eli Lilly entered into an agreement with Menarini International Operations Luxembourg SA, a company
Ved afgørelse af 2. august 2000 (herefter »den anfægtede afgørelse«) afviste Andet Appelkammer klagen for så vidt angik tjenesteydelserne i klasse 38, 41 og 42.
incorporated under Luxembourg law, for the licensing of its rights in the trade mark OPTRUMA and the promotion and distribution of that product in Italy.
Både Harmoniseringskontoret og sagsøgeren er af den opfattelse, at appelkammeret ved den anfægtede afgørelse afviste klagen, der var indbragt for dette, også hvad angik tjenesteydelserne i klasse 35.
After that meeting of the Pharmaceutical Committee, the applicant wrote to the Commission by letter dated 9 November 1999 and submitted various arguments in favour of the inclusion of the distributor's logo or that of the licence holder in the blue box of medicinal products authorised under the centralised procedure.
Harmoniseringskontoret har under retsmødet præciseret, at det forhold, at disse tjenesteydelser ikke var udtrykkeligt nævnt i den anfægtede afgørelse, efter dets opfattelse udgør en begrundelsesmangel ved afgørelsen.
Eli Lilly, as the marketing authorisation holder, submitted to the EMEA several mock-ups of the outer packaging of the product, which included, at least in the blue box of the Italian packaging, the name of the applicant in the form of a stylised 'M' together with the word 'Menarini'.
For så vidt appelkammeret traf afgørelse om klagen, fandt det i det væsentlige, at den pågældende ordkombination var omfattet af artikel 7, stk. 1, litra b) og c), i forordning nr. 40/94.
The head of the Pharmaceuticals and Cosmetics unit replied by letter of 22 November 1999 and stated that he saw 'no reason to object to such an inclusion [that of the logo of the local representative] for identification purposes'. He also stated:
Den anfægtede afgørelse blev meddelt sagsøgeren den 11. august 2000. Meddelelsen, der var dateret den 4. august 2000, nævnte, at den meddelte afgørelse var en afgørelse fra Første Appelkammer.
In February 1999, the EMEA expressed the opinion that the proposed packaging was unacceptable on the ground that the applicant's logo should not appear in the blue box and it referred the applicant to the Commission for further discussions.
Parternes påstande
'However — as this issue has not been discussed with Member States before I consider it necessary to raise this point at the occasion of the next Pharmaceutical Committee in March 2000 with a view to obtaining the agreement of Member States to an amendment of the respective Guideline.'
Sagsøgeren har nedlagt påstand om annullation af den anfægtede afgørelse.
It enclosed a letter from Eli Lilly, dated 17 May 1999, which was headed: 'Request to include the logo in the blue box'.
Appelkammeret undlod således at træffe afgørelse vedrørende den for dette indbragte klage, for så vidt denne var rettet mod undersøgerens afgørelse vedrørende tjenesteydelserne i klasse 35.
By letter dated 9 June 1999, the deputy head of the Pharmaceuticals and Cosmetics Unit replied as follows:
Den anfægtede afgørelses lovlighed, idet appelkammeret undlod at træffe afgørelse vedrørende den indbragte klage
However, we will raise this point at the occasion of the next Pharmaceutical Committee in September 1999 with a view to obtaining the agreement of Member States to an amendment of the respective Guideline.'
Sagsøgeren har under retsmødet erklæret, at stævningen ikke skal forstås således, at selskabet gør et anbringende gældende om en fejl i proceduren for meddelelse af den anfægtede afgørelse.
A large majority of the Member States' representatives declared that they considered the inclusion of the local representative's logo on the packaging of products authorised under the centralised procedure to be unacceptable.
I øvrigt er en fejl i forbindelse med proceduren for meddelelse af en afgørelse ifølge fast retspraksis retsaktens indhold uvedkommende og kan derfor ikke behæfte den med en mangel.
The main supporting argument put forward was that the indication of the name of a 'local representative' has to serve as a national contact point for patients and that it is not necessary for health purposes to add a company logo to this information.
Selv om det antages, at de bestemmelser, der regulerer meddelelsen af en afgørelse, udgør en væsentlig formforskrift, skal det fastslås, at der i denne sag ikke er sket tilsidesættelse af nogen væsentlig formforskrift.
Moreover, certain delegations raised the point that such an inclusion would create confusion for the patient between the marketing authorisation holder (who bears all the responsibility for the product) and the local representative who — by definition — has none.
Således som det er udtalt ovenfor, undlod appelkammeret at træffe afgørelse om sagsøgerens påstande for så vidt angik tjenesteydelserne i klasse 35.
By letter of 17 April 2000, received by the applicant on 26 April 2000 (hereinafter 'the contested decision'), the defendant informed the
Under disse omstændigheder kan Retten omgøre den anfægtede afgørelse, idet den træffer en realitetsafgørelse af spørgsmålet om, hvorvidt det ansøgte varemærke er omfattet af artikel 7, stk. 1, litra b), og/eller litra c), i forordning nr. 40/94 for så vidt angår disse tjenesteydelser.
The 48th meeting of the Pharmaceutical Committee on 27 and 28 September 1999 discussed the issue of the use of a logo on the outer packaging of a product authorised under the centralised procedure.
i svarskriftet og under retsmødet erklæret, at dette efter dets opfattelse ikke er tilfældet.
applicant that the request for the inclusion of the applicant's logo in the blue box had been definitively rejected.
Det er imidlertid ikke tilfældet, når appelkammeret ikke har truffet realitetsafgørelse om påstandene i deres helhed, således som det er tilfældet i denne sag.
Guideline on the packaging information of medicinal products, in that it could be interpreted as containing a prohibition on the use of the logo by the local representative or a licensee.
Den anfægtede afgørelse kan dermed ikke omgøres i denne sag.
In the contested decision the Commission states that:
I denne sag har appelkammeret, idet det undlod at træffe afgørelse om sagsøgerens påstande for så vidt angik tjenesteydelserne i klasse 35, tilsidesat den pligt, der følger af artikel 62, stk. 1, første punktum, i forordning nr. 40/94.
'Although certain Member States' representatives supported the proposal, the large majority of them was against the inclusion of the "local representative" logo on the packaging of pharmaceutical products authorised according to the centralised procedure.
Den anfægtede afgørelse skal derfor annulleres, idet appelkammeret undlod at træffe afgørelse om sagsøgerens påstande for så vidt angik tjenesteydelserne i klasse 35.
In support of its action, the applicant relies on seven pleas in law: first, lack of any legal basis in the Community legislation allowing the Commission to prohibit the applicant from including its logo on the outer packaging of the medicinal product OPTRUMA; second, breach of the applicant's right to property; third, breach of the principle of non-discrimination; fourth, breach of the principle of protection of legitimate expectations; fifth, breach of the obligation to state reasons; sixth, breach of the principle of proportionality and of the right freely to pursue economic activities; seventh, that the Commission was time-barred from adopting the decision.
Det skal endvidere bemærkes, at for at være omfattet af artikel 7, stk. 1, litra c), skal et varemærke »udelukkende« bestå af tegn eller angivelser, der kan tjene til at betegn de pågældende varers eller tjenesteydelsers egenskaber.
This position was principally motivated by the fact that the company logo would not add anything to the information which is necessary for health instructions, as the sole indication of the name and address of the "local representative" would in itself be sufficient to guarantee a national contact for the patients.
Det følger imidlertid af dette krav, at der ved et ordmærke, der er sammensat af flere bestanddele (eller et sammensat varemærke), skal tages hensyn til den relevante betydning af det ansøgte ordmærke, hvilken fastslås på grundlag af alle de bestanddele, varemærket er sammensat af, og ikke alene betydningen af en af disse bestanddele.
Moreover, certain delegations have stressed that such an inclusion might create confusion between the owner of the marketing authorisation (who is responsible for the product) and the local representative who — by definition is not responsible for the product.
Endvidere skal der ved denne bedømmelse alene tages hensyn til de egenskaber ved de pågældende varer eller tjenesteydelser, der kan få betydning ved det valg, der foretages af den relevante omsætningskreds. Et sammensat ordmærke skal følgelig for at kunne anses for at være beskrivende alene betegne sådanne egenskaber.
In its first plea, alleging lack of any legal basis for prohibiting the applicant from including its logo on the outer packaging of OPTRUMA, the applicant submits, first, that the essential aim of the Community provisions on the labelling and packaging of medicinal products, laid down in Directive 92/27, is to provide a high degree of consumer protection.
Den anfægtede afgørelses lovlighed, for så vidt appelkammeret traf realitetsafgørelse om den indbragte klage
The Commission services feel bound by the clear position expressed within the context of the Pharmaceutical Committee, not only in view of the large majority of opponents but also because of the fact that any modification to the "blue box Guideline", which would allow inclusion of the "local representative" logo, would require the support of the Committee itself.
— Anbringendet om tilsidesættelse af artikel 7, stk. 1, litra c), i forordning nr. 40/94
Therefore, on the basis of the abovementioned considerations, the proposal to include the "local representative" logo on the packaging of pharmaceutical products authorised according to the centralised procedure is not accepted.'
Sagsøgeren og Harmoniseringskontoret er af den opfattelse, at det ansøgte varemærke ikke er omfattet af artikel 7, stk. 1, litra c), i forordning nr. 40/94.
The person responsible for placing the product on the market has various obligations in particular, with respect to the provision of scientific information and pharmacovigilance.
1 finder anvendelse, selv om registreringshindringerne kun er til stede i en del af Fællesskabet«.
By application lodged at the Registry of the Court on 3 July 2000 the applicant brought the present action.
— Anbringendet om tilsidesættelse af artikel 7, stk. 1, litra b), i forordning nr. 40/94
It is therefore important that the person responsible for placing the product on the market can be easily and correctly identified as such by both the user and the health professionals using the medicinal products in question, where necessary by means of the company's logo, which cannot be separated from its name and business identity.
Sagsøgeren har påstået, at den pågældende ordkombination, der består af en typisk
annul the contested decision; in the alternative, declare illegal under Article 241 EC the European Commission's
For så vidt angår et sammensat varemærke skal det fornødne særpræg bedømmes ud fra helhedsindtrykket.
The question is whether, under Article 2(2) of the directive, the applicant's name and/or logo may be included on the packaging as 'other information which is useful for health education'.
Dette er imidlertid ikke uforeneligt med en undersøgelse af de forskellige træk, som tegnet består af, hver for sig (Rettens dom i sagen Procter & Gamble mod KHIM, præmis 59). Harmoniseringskontoret har gjort gældende, at bestanddelen »SAT«, der er beskrivende for de pågældende tjenesteydelser, i sig selv mangler fornødent særpræg i forhold til disse tjenesteydelser.
box (section C, point 5). Likewise, at its 48th meeting the Pharmaceutical Committee took the view that the inclusion on the outer packaging of the logo of the company holding the marketing authorisation should be accepted for identification reasons.
Harmoniseringskontoret har endvidere påstået, at tilføjelsen af tallet »2« ikke udgør et supplerende element, der kan give den pågældende ordkombination — set i sin helhed — det fornødne særpræg.
The logo plays an important role in identifying a company operating on the market.
Harmoniseringskontoret er i denne forbindelse af den opfattelse, at tilføjelsen af et tal er helt gængs i sektoren for tjenesteydelser, der har forbindelse med medierne.
Its function is to constitute a unit in combination with the name of the company in order to facilitate identification of that company.